文献速递妇科肿瘤

双染与HPV分型用于HPV阳性女性宫颈癌筛查分流的长期前瞻性队列研究

Long-Term Prospective Cohort Study of Cervical Cancer Screening Using Triage of Women Who Are Human Papillomavirus-Positive With Dual Stain and Human Papillomavirus Genotyping.
PubMed 文献 · J Clin Oncol · 2026-02-17

该研究在Kaiser Permanente北加州系统纳入9645名HPV阳性接受宫颈筛查的女性,评估双染(DS)和细胞学对CIN3+的检出效能及5年累积风险。结果显示DS阴性者基线CIN3+风险仅0.8%,DS在敏感性、特异性及预测值上均优于细胞学(P<.001),且在各年龄组及非HPV16/18阳性者中分流性能更佳。

要点

  • DS阴性者CIN3+基线风险0.8%,支持长期低风险 reassurance。
  • DS对CIN3+的敏感性、特异性及预测值均优于细胞学(P<.001)。
  • HPV16阳性且DS阴性者风险2.9%,仍高于DS阴性总体但低于HPV16阳性/NILM的7.5%。

核心结论

  • DS阴性提示低风险可长期放心,DS较细胞学更早检出致癌分子改变。
  • DS overall及在HPV风险分层内、各筛查年龄组中风险分层均优于细胞学。
  • DS是接种疫苗人群分流的更优选择。

研究设计与样本

  • 前瞻性观察性研究,纳入2015至2017年两个时段Kaiser Permanente北加州组织性宫颈筛查中9645名连续HPV阳性女性。
  • 采用患病率-发病率混合模型估算5年CIN3+累积绝对风险。

主要发现

  • DS阳性与阴性者CIN3+基线风险分别为9.4%与0.8%。
  • 细胞学阳性与阴性者CIN3+基线风险分别为6.9%与2.0%。
  • 5年内DS对CIN3+检出的敏感性、特异性及预测值均优于细胞学(所有比较P<.001)。
  • HPV16阳性/NILM者风险7.5%,显著高于HPV16阳性/DS阴性者的2.9%(P<.001)。
  • DS在各年龄组及非HPV16/18阳性女性中分流性能均优于细胞学。

临床怎么用

  • 对HPV阳性女性可采用DS分流,DS阴性者风险低可延长随访间隔。
  • HPV16阳性者即使DS阴性仍需关注,其风险高于DS阴性总体。
  • 在接种HPV疫苗人群中优先考虑DS作为分流工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Primary human papillomavirus (HPV) testing has the best tradeoff of benefits and harms for cervical screening but requires triage to determine management among HPV positives. We conducted a prospective observational study to evaluate triage of women who are HPV-positive using dual stain (DS) and HPV genotyping. MATERIALS AND METHODS: We included 9,645 consecutive women who are HPV-positive undergoing cervical screening in two periods between 2015 and 2017 in the organized cervical screening program at Kaiser Permanente Northern California. Absolute risk and clinical performance of DS and cytology for detection of cervical intraepithelial neoplasia grade 3 and greater (CIN3+) were estimated overall and by HPV genotype and by age. Cumulative absolute risk of CIN3+ was modeled over 5 years using a prevalence-incidence mixture model, which allows estimating risk accounting for differences in disease ascertainment, surveillance intervals, and compliance. RESULTS: The baseline risk of CIN3+ was 9.4% and 0.8% for women testing positive and negative for DS, respectively, and 6.9% and 2.0% for women testing positive and negative for cytology, respectively. Sensitivity, specificity, and predictive values for CIN3+ detection were better for DS compared with cytology over 5 years (P < .001 for all comparisons). Risk in women with HPV16-positive/negative for intraepithelial lesion or malignancy was substantially higher than the risk in women with HPV16-positive/DS-negative (7.5% v 2.9%, P < .001). DS had better triage performance compared with cytology in all age groups and in women positive for HPV types other than HPV16 or HPV18. CONCLUSION: Long-term reassurance of low risk among DS negatives suggests that DS detects molecular changes earlier in the carcinogenic pathway than cytology. DS has better risk stratification than cytology overall, within HPV risk strata, and across all screening age groups and is a better option for triage of vaccinated populations.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wentzensen N, Egemen D, Clarke MA, et al. Long-Term Prospective Cohort Study of Cervical Cancer Screening Using Triage of Women Who Are Human Papillomavirus-Positive With Dual Stain and Human Papillomavirus Genotyping. J Clin Oncol. 2026. PMID: 41701950. doi:10.1200/JCO-25-00689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。